Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Galapagos to review future of Jyseleca

Written by | 8 Aug 2023 | Pharma News

Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023 which show that Jyseleca (filgotinib), approved in Europe for rheumatoid arthritis and ulcerative colitis, reached €54.3 million in sales, up by 54% on the like, year-earlier period but below consensus estimates.

The decline was due to the European Commission’s endorsement of the recommendation of its Pharmaceutical Risk Assessment Committee, following similar guidance in the US, to place restrictions on the use of all drugs in the JAK inhibitor class in certain patient groups including those aged 65 years or older.

The market and competitive landscape for the JAK class in Europe has changed significantly over the past six months. As a result, full-year 2023 sales guidance for Jyseleca has been cut to €100 million-€120 million from €140 million -€160 million.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.